\n \n\n \n \n \n \n NDA\n \n \n\n \n\n\n
\n \n \n \nHow can we get patients safely off the ventilators following a traumatic brain injury or neurosurgery?\r\nHow do we plan to avoid unnecessary re-intubations and prolonged ventilation?\r\nHow could we reduce ventilator days and length of stay in ICU?
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nUnderstanding Cerebellar Development and Disease
\n \n\n \n \n\n \n\n \n \n \n \n MRC BNDU\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n NLO\n \n \n\n \n\n\n
\n \n \n \nThe Xue Lab is a translational research group investigating the mechanisms of retinal inflammation and degeneration in the context of age-related macular degeneration (AMD), uveitis and retinal gene therapy. Our aim is to translate improved understanding of disease mechanisms into clinical trials for patients with retinal diseases, and ultimately new therapies to prevent sight loss.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nGlycosylation is one of the most common and poorly understood forms of post-translational modification. Our aim is to understand the biochemical mechanisms underlying protein glycosylation, as well as decipher the roles that they play in health and disease.
\n \n\n \n \n\n \n\n \n \n \n \n NDA\n \n \n\n \n\n\n
\n \n \n \nOur group uses multimodal neuroimaging to understand the changes in the brain under anaesthesia and during altered states of consciousness. We aim to translate these findings to the clinical environment to improve patient treatment and outcomes.
\n \n\n \n \nThe Oxford University Global Surgery Group brings together Medical Sciences Division clinicians in surgery, anaesthesia, obstetrics and gynaecology with an interest in global surgical issues.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur group applies computational models to study changes in motivation, memory and decision-making that occur in neurological disease. We combine behavioural, neuroimaging, and pharmacological experiments to apply mathematical models to clinical problems.
\n \n\n \n \nProfessor Colin Espie is the Director, and Dr. Simon Kyle the Deputy Director, of the Experimental and Clinical Sleep Medicine group with the Sleep and Circadian Neuroscience Institute, University of Oxford. We conduct human experimental and clinical studies on sleep and disorders of sleep with the aim of understanding their pathophysiology and in the mechanisms of action of treatments. Our research is supported by numerous national and international funders, including the Wellcome Trust, NIHR, Swiss National Science Foundation, Education Endowment Fund, and the Dr. Mortimer and Theresa Sackler Foundation, amongst others.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe bring together biomedical, analytical and clinical expertise to shed new light on the causes that underpin neurodegenerative diseases.
\n \n\n \n \n\n \n\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nDrug discovery in neuroscience is very challenging but the need is greater than ever. Perhaps the most important factor for successfully developing an effective therapy, is the identification of human disease relevant drug targets. Our group aims to elucidate the pathophysiological basis of human neurological disorders from genetic molecular networks to complex neural systems using human genetics, human models and human tissue wherever possible.
\n \n\n \n \n\n \n\n \n \n \n \n NDA\n \n \n\n \n\n\n
\n \n \n \nHow can we make sure people are fit for surgery, improve safety in the operating theatre, and ensure better recovery after major operations?
\n \n\n \n \n\n \n\n \n \n \n \n NDA\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur group aims to achieve a better understanding of what happens in the brains of patients who have just had a subarachnoid haemorrhage, which is a type of stroke.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nCPSD runs several research studies looking into the causes, investigation, and management of large artery atherosclerosis, carotid stenosis, vertebral artery disease and intracranial atherosclerosis.
\n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nThe Oxford Project to Investigate Memory and Ageing (OPTIMA) started in 1988 and the last LEAD participants were seen in March 2015. We are no longer recruiting to any of the cohorts. However, we are currently creating the OPTIMA Legacy Resource from which data collected from the OPTIMA cohorts is available and samples are biobanked and available. Brain tissue is available as part of the Brains For Dementia Research (BDR) collection.
\n \n\n \n \n\n \n\n \n \n \n \n CPSD\n \n \n\n \n\n\n
\n \n \n \nThe Oxford Vascular Study (OxVasc) investigates vascular diseases (e.g. strokes, heart attacks) in patients registered with eight general practices in Oxfordshire. We run a rapid-access clinic for patients with suspected Transient Ischaemic Attacks (TIAs) or minor strokes.
\n \n\n \n \n\n \n\n \n \n \n \n FMRIB\n \n \n\n \n\n\n
\n \n \n \nBeliefs shape our perception of pain. Using non-invasive magnetic resonance imaging in humans, we investigate how beliefs are generated, maintained and revised in the brain and how they influence pain perception.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n \n \n NDCN\n \n \n\n \n\n\n
\n \n \n \nOur objective is to develop ways of accurately measuring neurological disorders such as Parkinson's disease.
\n \n\n \n \n\n \n\n \n \n \n \n DCN\n \n \n\n \n\n\n
\n \n \n \nWe study why certain neuronal populations are vulnerable to neurodegeneration in Parkinson\u2019s disease brain and whether pathological changes seen in the peripheral tissues mirror or precede what is ultimately seen in the brain, and how this can be used to develop biomarkers.
\n \n\n \n \n